A Phase III, Open-Label, Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects with Refractory Generalized Myasthenia Gravis (gMG)/ Alexion ECU-MG-302

Trial ID or NCT#

NCT02301624

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to determine if eculizumab is safe and effective for the treatment of patients with refractory gMG.

Investigator(s)

Srikanth Muppidi, MD

View on ClinicalTrials.gov